LISATA THERAPEUTICS AND CATALENT ANNOUNCE GLOBAL ANTIBODY-DRUG CONJUGATE (ADC) LICENSE AGREEMENT
LISATA THERAPEUTICS INC - TO RECEIVE OVER $10 MILLION IN MILESTONE PAYMENTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.